Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

47,000

Sector

Pharmaceuticals

Calendar

02-10 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/12/25	1,027.51 $	+1.80%	3,275,239
11/12/25	1,009.38 $	+1.58%	4,516,960
10/12/25	993.64 $	+1.16%	2,966,270
09/12/25	982.22 $	-1.54%	2,569,724
08/12/25	997.59 $	-1.26%	3,088,557

Delayed Quote Nyse, December 12, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 03:39 pm

Is it back to square one for Eli Lilly?

August 07, 2025 at 04:20 pm

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,027.51USD

Average target price

1,075.74USD

Spread / Average Target

+4.69%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:02 12/12/2025 GMT			5-day change	1st Jan Change
1,027.51 ^USD	+1.80%		+1.70%	+33.10%

12-12	Health Care Flat on Defensive Bias - Health Care Roundup	DJ
12-12	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Capitalization	920B 784B 732B 689B 1,268B 83,330B 1,385B 8,545B 3,315B 39,280B 3,452B 3,379B 143,308B	P/E ratio 2025 *	44.9x	P/E ratio 2026 *	32.5x
Enterprise value	945B 805B 752B 708B 1,303B 85,589B 1,423B 8,777B 3,405B 40,345B 3,546B 3,471B 147,194B	EV / Sales 2025 *	14.9x	EV / Sales 2026 *	12.2x
Free-Float	99.81%	Yield 2025 *	0.58%	Yield 2026 *	0.65%

12-12	Health Care Flat on Defensive Bias - Health Care Roundup	DJ
12-12	Sector Update: Health Care Stocks Advance Late Afternoon	MT
12-12	SOFTS-Raw sugar closes up 1.7% on bullish technical signals; robusta coffee finishes at close to four-month low	RE
12-12	Sector Update: Health Care Stocks Edge Higher Friday Afternoon	MT
12-12	Sector Update: Health Care	MT
12-12	Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo? (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer	CI
12-12	Eli Lilly Inluriyo Shows 38% Risk Reduction, Extends Median Survival in Advanced Breast Cancer	MT
12-12	SOFTS-Raw sugar gains on bullish technical signals; robusta coffee slides	RE
12-12	Ozempic launches in India at $24 a week as Novo targets booming market	RE
12-12	Rate Cuts Can't Buy Confidence
12-12	EU committee backs extending use of Lilly's diabetes drug for children aged 10 and above	RE
12-12	FDA reportedly seeks to expedite review of Lilly's weight loss pill - Reuters	FW
12-12	Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026	MT

12-12	Analyst recommendations: Lululemon, Snap, Broadcom, Roblox, SanDisk…
12-11	Roche Kept at Buy as BofA Notes 'Positive' Late-stage Pipeline Data	MT
12-10	Wells Fargo Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Overweight Rating	MT
12-10	HSBC Adjusts PT on Eli Lilly and Company to $1,070 From $850, Maintains Hold Rating	MT
12-10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…

Eli Lilly and Company Share Price

Equities

LLY

US5324571083

Pharmaceuticals

Valuation: Eli Lilly and Company

Chart: Eli Lilly and Company

Latest news: Eli Lilly and Company

Last Transcript: Eli Lilly and Company

Analysts' recommendations: Eli Lilly and Company

Press Releases: Eli Lilly and Company

News in other languages: Eli Lilly and Company

Trading Eli Lilly and Company

Quotes and Performance

Course Extremes

Managers and Directors: Eli Lilly and Company

ETFs: Eli Lilly and Company

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-12	Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer	PR
12-11	Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial	PR
12-09	Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama	PR
12-09	Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL	PR
12-08	Lilly declares first-quarter 2026 dividend	PR

12-12	Wall Street : Les baisses de taux ne vendent plus du rêve
12-12	Wall Street sans direction claire ; Oracle en chute libre
12-11	MÄRKTE USA/Dow auf Rekordhoch - Oracle bremst KI-Technologieaktien
12-11	MÄRKTE USA/Uneinheitlich - Dow fest - Nasdaq-Indizes geben nach
12-11	Eli Lilly: Neue Abnehmspritze lindert auch Gelenkschmerzen deutlich

1 day	+1.80%
1 week	+1.70%
Current month	-4.46%
1 month	+0.22%
3 months	+36.02%
6 months	+25.40%
Current year	+33.10%

1 week	977.12	1,031.56
1 month	977.12	1,111.99
Current year	623.78	1,111.99
1 year	623.78	1,111.99
3 years	302.14	1,111.99
5 years	161.78	1,111.99
10 years	64.18	1,111.99

Manager	Title	Age	Since
David Ricks CEO	Chief Executive Officer	57	31/12/2016
Ruth Gimeno PSD	President	-	-
Lucas Montarce DFI	Director of Finance/CFO	48	08/09/2024

Director	Title	Age	Since
Jon Fyrwald BRD	Director/Board Member	65	31/12/2004
Ralph Alvarez BRD	Director/Board Member	69	31/03/2009
Katherine Baicker BRD	Director/Board Member	53	11/12/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ELI LILLY AND COMPANY	+1.80%	+1.70%	+30.21%	+182.67%	920B
JOHNSON & JOHNSON	+0.75%	+4.78%	+44.31%	+17.70%	510B
ABBVIE INC.	-0.29%	-1.22%	+28.81%	+35.46%	395B
ROCHE HOLDING AG	-0.35%	+1.90%	+25.12%	+3.01%	340B
ASTRAZENECA PLC	-1.12%	-1.09%	+28.43%	+17.93%	278B
NOVARTIS AG	-0.45%	-1.48%	+20.24%	+22.49%	254B
MERCK & CO., INC.	+1.30%	+0.58%	-1.67%	-10.09%	249B
NOVO NORDISK A/S	+0.45%	+3.73%	-57.41%	-31.49%	224B
AMGEN INC.	+0.11%	-3.68%	+17.41%	+17.19%	171B
GILEAD SCIENCES, INC.	-2.28%	-0.68%	+31.08%	+36.20%	149B
Average	-0.01%	+0.45%	+16.65%	+29.11%	349.14B
Weighted average by Cap.	+0.42%	+1.07%	+22.26%	+57.74%

	2025 *	2026 *
Net sales	63.58B 54.16B 50.59B 47.6B 87.64B 5,759B 95.74B 591B 229B 2,714B 239B 234B 9,903B	76.3B 65B 60.72B 57.13B 105B 6,911B 115B 709B 275B 3,258B 286B 280B 11,885B
Net income	20.4B 17.38B 16.23B 15.27B 28.12B 1,848B 30.72B 189B 73.49B 871B 76.54B 74.93B 3,177B	28.05B 23.89B 22.32B 21B 38.66B 2,540B 42.24B 261B 101B 1,197B 105B 103B 4,369B
Net Debt	24.95B 21.25B 19.85B 18.68B 34.39B 2,259B 37.57B 232B 89.88B 1,065B 93.6B 91.63B 3,886B	10.94B 9.32B 8.7B 8.19B 15.08B 991B 16.47B 102B 39.41B 467B 41.04B 40.18B 1,704B